Terns Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $447.13 million
- Book Value:
- Revenue TTM:
- $1 million
- Operating Margin TTM:
- Gross Profit TTM:
- $1 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Terns Pharmaceuticals Inc had its IPO on 2021-02-05 under the ticker symbol TERN.
The company operates in the Healthcare sector and Biotechnology industry. Terns Pharmaceuticals Inc has a staff strength of 41 employees.
Shares of Terns Pharmaceuticals Inc opened at $8.96 at the start of the last trading session i.e. 2023-03-22.
The stocks traded within a range of $8.76 - $9.27, and closed at $8.81.
This is a -2.44% slip from the previous day's closing price.
A total volume of 166,221 shares were traded at the close of the day’s session.
In the last one week, shares of Terns Pharmaceuticals Inc have slipped by -8.7%.
Terns Pharmaceuticals Inc's Key Ratios
Terns Pharmaceuticals Inc has a market cap of $447.13 million, indicating a price to book ratio of 1.3392 and a price to sales ratio of 256.5261.
In the last 12-months Terns Pharmaceuticals Inc’s revenue was $1 million with a gross profit of $1 million and an EBITDA of $-58574000. The EBITDA ratio measures Terns Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Terns Pharmaceuticals Inc’s operating margin was -5907.9% while its return on assets stood at -19.83% with a return of equity of -33.03%.
In Q3, Terns Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Terns Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.03 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Terns Pharmaceuticals Inc’s profitability.
Terns Pharmaceuticals Inc stock is trading at a EV to sales ratio of 60.0754 and a EV to EBITDA ratio of -1.0328. Its price to sales ratio in the trailing 12-months stood at 256.5261.
Terns Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $192.59 million
- Total Liabilities
- $7.48 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Terns Pharmaceuticals Inc ended 2023 with $192.59 million in total assets and $0 in total liabilities. Its intangible assets were valued at $192.59 million while shareholder equity stood at $183.69 million.
Terns Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $7.48 million in other current liabilities, 4000.00 in common stock, $-226596000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $62.98 million and cash and short-term investments were $187.29 million. The company’s total short-term debt was $665,000 while long-term debt stood at $0.
Terns Pharmaceuticals Inc’s total current assets stands at $190.54 million while long-term investments were $0 and short-term investments were $124.31 million. Its net receivables were $0 compared to accounts payable of $2.09 million and inventory worth $0.
In 2023, Terns Pharmaceuticals Inc's operating cash flow was $-1240000.00 while its capital expenditure stood at $8000.
Comparatively, Terns Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Terns Pharmaceuticals Inc stock is currently trading at $8.81 per share. It touched a 52-week high of $11.44 and a 52-week low of $11.44. Analysts tracking the stock have a 12-month average target price of $12.6.
Its 50-day moving average was $9.49 and 200-day moving average was $6.07 The short ratio stood at 4.14 indicating a short percent outstanding of 0%.
Around 248.5% of the company’s stock are held by insiders while 11062.7% are held by institutions.
Frequently Asked Questions About Terns Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.